Christian Philipp Reinert1, Martin Ulrich Schuhmann2,3, Benjamin Bender4, Isabel Gugel2,3, Christian la Fougère5, Jürgen Schäfer6, Sergios Gatidis6. 1. Department of Diagnostic and Interventional Radiology, University Hospital Tuebingen, Hoppe-Seyler-Str.3, 72076, Tuebingen, Germany. christian.reinert@med.uni-tuebingen.de. 2. Department of Neurosurgery, University Hospital Tuebingen, Hoppe-Seyler-Str.3, 72076, Tuebingen, Germany. 3. Centre of Neurofibromatosis, Centre of Rare Diseases, University Hospital Tuebingen, Hoppe-Seyler-Str.3, 72076, Tuebingen, Germany. 4. Department of Diagnostic and Interventional Neuroradiology, University Hospital Tuebingen, Hoppe-Seyler-Str.3, 72076, Tuebingen, Germany. 5. Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Hoppe-Seyler-Str.3, 72076, Tuebingen, Germany. 6. Department of Diagnostic and Interventional Radiology, University Hospital Tuebingen, Hoppe-Seyler-Str.3, 72076, Tuebingen, Germany.
Abstract
PURPOSE: To demonstrate the clinical use of FDG-PET/MRI for monitoring enlargement and metabolism of plexiform neurofibromas (PNF) in patients with neurofibromatosis type 1 (NF1), in whom the development of a malignant peripheral nerve sheath tumor (MPNST) is often a life limiting event. METHODS: NF1 patients who underwent a simultaneous FDG-PET/MRI examination in our institution from September 2012 to February 2018 were included. Indication was suspicion of malignant transformation of a PNF to MPNST. A maximum of six peripheral nerve lesions per patient were defined as targets. Standardized uptake values (SUV) and apparent diffusion coefficients (ADC) were measured. The presence of target sign and contrast-medium enhancement was visually recorded. Growth rates were estimated comparing prior or follow-up examinations and correlated with FDG uptake and ADC values. The presence of CNS lesions in cerebral T2 weighted images was recorded. RESULTS: In 28 NF1 patients a total number of 83 peripheral nerve tumors, 75 benign PNFs and eight MPNSTs, were selected as target lesions. The SUVs of MPNSTs were significantly higher than the SUVs of PNF (3.84 ± 3.98 [SUVmean MPNSTs] vs. 1.85 ± 1.03 [SUVmean PNF], P < .01). Similarly, lesion SUVmean-to-liver SUVmean ratios significantly differed between MPNSTs and PNF (3.20 ± 2.70 [MPNSTs] vs. 1.23 ± 0.61 [PNF]; P < .01). For differentiation between still benign PNF and MPNSTs, we defined SUVmax ≥ 2.78 as a significant cut-off value. Growth rate of PNF correlated significantly positively with SUVmean (rs = .41; P = .003). MRI parameters like ADCmean (1.87 ± 0.24 × 10-3 mm2/s [PNF] vs. 1.76 ± 0.11 × 10-3 mm2/s [MPNSTs]; P > .05], contrast medium enhancement (P = .50) and target sign (P = .86) did not differ between groups. CONCLUSION: Simultaneous FDG-PET/MRI is a comprehensive imaging modality for monitoring PNF in NF1 patients. The combined acquisition of both morphologic information in MRI and metabolic information in PET enables the correlation of lesion growth rates with metabolic activity and to define SUV thresholds of significance to identify malignant transformation, which is of utmost clinical significance.
PURPOSE: To demonstrate the clinical use of FDG-PET/MRI for monitoring enlargement and metabolism of plexiform neurofibromas (PNF) in patients with neurofibromatosis type 1 (NF1), in whom the development of a malignant peripheral nerve sheath tumor (MPNST) is often a life limiting event. METHODS:NF1patients who underwent a simultaneous FDG-PET/MRI examination in our institution from September 2012 to February 2018 were included. Indication was suspicion of malignant transformation of a PNF to MPNST. A maximum of six peripheral nerve lesions per patient were defined as targets. Standardized uptake values (SUV) and apparent diffusion coefficients (ADC) were measured. The presence of target sign and contrast-medium enhancement was visually recorded. Growth rates were estimated comparing prior or follow-up examinations and correlated with FDG uptake and ADC values. The presence of CNS lesions in cerebral T2 weighted images was recorded. RESULTS: In 28 NF1patients a total number of 83 peripheral nerve tumors, 75 benign PNFs and eight MPNSTs, were selected as target lesions. The SUVs of MPNSTs were significantly higher than the SUVs of PNF (3.84 ± 3.98 [SUVmean MPNSTs] vs. 1.85 ± 1.03 [SUVmean PNF], P < .01). Similarly, lesion SUVmean-to-liver SUVmean ratios significantly differed between MPNSTs and PNF (3.20 ± 2.70 [MPNSTs] vs. 1.23 ± 0.61 [PNF]; P < .01). For differentiation between still benign PNF and MPNSTs, we defined SUVmax ≥ 2.78 as a significant cut-off value. Growth rate of PNF correlated significantly positively with SUVmean (rs = .41; P = .003). MRI parameters like ADCmean (1.87 ± 0.24 × 10-3 mm2/s [PNF] vs. 1.76 ± 0.11 × 10-3 mm2/s [MPNSTs]; P > .05], contrast medium enhancement (P = .50) and target sign (P = .86) did not differ between groups. CONCLUSION: Simultaneous FDG-PET/MRI is a comprehensive imaging modality for monitoring PNF in NF1patients. The combined acquisition of both morphologic information in MRI and metabolic information in PET enables the correlation of lesion growth rates with metabolic activity and to define SUV thresholds of significance to identify malignant transformation, which is of utmost clinical significance.
Authors: Johannes Salamon; Simon Veldhoen; Ivayla Apostolova; Peter Bannas; Jin Yamamura; Jochen Herrmann; Reinhard E Friedrich; Gerhard Adam; Victor F Mautner; Thorsten Derlin Journal: Eur Radiol Date: 2013-10-05 Impact factor: 5.315
Authors: Jürgen F Schäfer; Sergios Gatidis; Holger Schmidt; Brigitte Gückel; Ilja Bezrukov; Christina A Pfannenberg; Matthias Reimold; Martin Ebinger; Jörg Fuchs; Claus D Claussen; Nina F Schwenzer Journal: Radiology Date: 2014-05-31 Impact factor: 11.105
Authors: Matthias R Benz; Nishan Tchekmedyian; Fritz C Eilber; Noah Federman; Johannes Czernin; William D Tap Journal: Curr Opin Oncol Date: 2009-07 Impact factor: 3.645
Authors: Lucia Baratto; K Elizabeth Hawk; Lisa States; Jing Qi; Sergios Gatidis; Louise Kiru; Heike E Daldrup-Link Journal: J Nucl Med Date: 2021-10 Impact factor: 10.057
Authors: Maria Schwabe; Stanislav Spiridonov; Elizabeth L Yanik; Jack W Jennings; Travis Hillen; Maria Ponisio; Douglas J McDonald; Farrokh Dehdashti; Cara A Cipriano Journal: Sarcoma Date: 2019-07-01
Authors: Enrico Martin; Ritchie T J Geitenbeek; J Henk Coert; David F Hanff; Laura H Graven; Dirk J Grünhagen; Cornelis Verhoef; Walter Taal Journal: Neuro Oncol Date: 2021-04-12 Impact factor: 12.300
Authors: Ritch T J Geitenbeek; Enrico Martin; Laura H Graven; Martijn P G Broen; Monique H M E Anten; Jochem A J van der Pol; Cornelis Verhoef; Walter Taal Journal: J Neurooncol Date: 2022-01-13 Impact factor: 4.130